Alimentary pharmacology & therapeutics
-
Aliment. Pharmacol. Ther. · Jan 2013
Randomized Controlled Trial Multicenter StudyRandomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints.
Treatment options that improve overall symptoms of irritable bowel syndrome with constipation (IBS-C) are lacking. ⋯ Linaclotide treatment significantly improved abdominal pain/discomfort and degree-of-relief of IBS-C symptoms compared with placebo over 12 and 26 weeks.
-
Aliment. Pharmacol. Ther. · Jan 2013
Meta AnalysisSafety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program.
Non-alcoholic fatty liver disease has reached epidemic proportions in type 2 diabetes (T2D). Glucagon-like peptide-1 analogues are licensed in T2D, yet little data exist on efficacy and safety in liver injury. ⋯ Twenty-six weeks' liraglutide 1.8 mg is safe, well tolerated and improves liver enzymes in patients with type 2 diabetes. This effect appears to be mediated by its action on weight loss and glycaemic control.